Economic evaluation of cancer drugs : using clinical trial and real-world data /: using clinical trial and real-world data. (2019)

• Record Type: Book
• Further Information: Note: Iftekhar Khan, Ralph Crott, Zahid Bashir.
• Authors: (Statistician), Khan, Iftekhar; Crott, Ralph; Bashir, Zahid
• Contents: 1. Introduction to Cancer Cancer Epidemiology of Cancer Prognostic factors associated with cancer outcomes Economic Burden of Cancer Treatments for Cancer Important Economic Concepts for Cost-Effectiveness of Cancer interventions Health Economic Evaluation and Cancer Drug Development in Practice Efficacy versus Effectiveness Real World Data Economic versus Clinical Hypotheses Exercises 2. Introduction Important Common, Surrogate and Novel Cancer Endpoints Overall Survival Surrogate Endpoints HTAs with Surrogate Endpoints Emerging Tumour-Centred Endpoints Demonstrating Value from other cancer endpoints Exercises 3. Health Related Quality of Life for Cost-effectiveness Health Related Quality of Life (HRQoL) in cancer patients Measuring HRQoL for Economic Evaluation Constructing Utilities Quality Adjusted Life Years (QALYs) Economic Evaluation in the Absence of Utility Data: Mapping and Utility Studies Sensitivity and Responsiveness of EQ-D versus QLQ-C HRQoL for detecting improvement in cancer patients Measuring Post-Progression Utility: Some Approaches Plausible Post-Progression Utility Behaviour Non-Linear Models HRQoL issues in Health Technology Appraisals of Cancer Drugs Exercises 4. Introductory Statistical Methods for Economic Evaluation in Cancer Introduction Uncertainty and variability Distributions: Cost, Utility and Survival Data Important measures used in cancer trials Simulation: Bootstrapping and Monte-Carlo Simulation Analysing Data from cancer Trials Semi-Parametric Methods – The Cox PH model Parametric Methods: Modelling Survival Data for Extrapolation Advanced Modelling Techniques for Survival Data Issues in fitting models Handling Crossover, Treatment Switching and Subsequent anti-cancer therapy Data Synthesis and Network Meta Analyses Mixed Treatment Comparisons Assumptions for carrying out MTCs Exercises 5. Collecting and Analysis of Costs from Cancer Studies Types of costs typical of cancer trials Perspective of analysis and costs collection Collecting Health Resource use across the treatment pathway Costing methods: micro versus macro approach Charges Distribution of Costs Handling Censored and Missing Costs Strategies for avoiding missing resource data Strategies for analysing cost data when data are missing or censored Handling Future Costs Case Report Forms and Health Resource Use Statistical Analyses of Costs Exercises 6. Designing Cost-effectiveness into Cancer Trials Introduction and Reasons for Collecting Economic Data in a Clinical Trial Clinical Trial Designs for Cancer Studies Planning a Health Economic Evaluation in a Clinical Trial Important considerations when designing a cancer study for economic evaluation Integrating Economic Evaluation in a Clinical Trial: Considerations Figure : Clustered data within each centre Case study of Economic Evaluation of cancer trials Exercises 7. Models for Economic Evaluation of Cancer Types of Health Economic Models Decision Tree Models Markov Models Continuous time Markov Models The partitioned survival model Developing an economic model using patient level data using a partitioned survival model approach Case Study of an economic model using patient level data: a partitioned survival model Summary of Cost-Effectiveness Models for Cancer used in HTA submissions Exercises 8. Real World Data in Cost-Effectiveness studies on Cancer Introduction to Real World Data Using RWD to Support Cost-Effectiveness Analysis Strengths and Limitations of Using RWD to Support Cost-Effectiveness Analysis Internal Validity versus Generalizability Sources for RWD generation Using Cancer Registries Statistical Analyses of RWD: Addressing Selection Bias Propensity Score Modelling Instrumental Variable Methods Summary and Conclusion Exercises for Chapter 9. Reporting and Interpreting Results of Cost-effectiveness Analyses from Cancer trials Interpreting Incremental Costs and Utilities Interpreting Incremental QALYs Relationship between costs and QALYs Interpreting the ICER and the Cost-effectiveness Plane Presenting and interpreting results from uncertainty analyses Limitations of the ICER and using the INMB Presenting and interpreting results from Value of Information Analyses (VOI) Exercises 10. Important Lessons from Failed Reimbursement Attempts A List of rejected cancer drugs by NICE When it's useded Summary of criticisms of Economic Models of Cancer Factors Predictive of successful HTAs in Cancer The changing pace of the reimbursement environment Reimbursement and payer evidence requirements across different countries Pricing and reimbursement environment in United States Value based pricing (VBP) for Cancer Drugs Risk Sharing Scheme The Future of Cost-effectiveness of Cancer Treatments Future Research: Methodology Future Reimbursement Landscape
• Edition: 1st
• Publisher Details: Boca Raton : Chapman & Hall/CRC
• Publication Date: 2019
• Extent: 1 online resource, illustrations (black and white)
• Subjects: 615.798; Antineoplastic agents -- Development -- Economic aspects; Clinical trials -- Economic aspects; Medical economics
• Languages: English
• ISBNs: 9780429531842; 9781498761314; 9780429546549; 9780429155826
• Related ISBNs: 9781498761307
• Notes: Note: Description based on CIP data; resource not viewed.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.